The focus was on a short fragment of ACTH, Pro8-Gly9-Pro10 ACTH(4-10) and by dissociation of the combination of amino acids, substitution and special linkages a peptide was synthesized which had unique neuroregulatory properties.
Extensive testing over a period of 14 years resulted in the approval of the Russian Federation Ministry of Public Health and Pharmaceutical Industry on 28 March, 1996, for the clinical use of SEMAX® in the Russian Federation as a neuroactive peptide with endogenous regulatory properties affecting cerebral cellular processes which are beneficial in protecting and enhancing the recovery of cerebral functions after ischemic insults like : brain stroke, closed head injuries. Neurodegenerative processes like in Alzheimer’s disease, Parkinson’s disease and Huntington’s Chorea.

SEMAX® also influences the intellectual capacities and memory as well as concentration of normal, healthy persons subjected to stressful working conditions, increasing their mental capacities and diminishing the index of workload.